SOCS3 in immune regulation of inflammatory bowel disease and inflammatory bowel disease-related cancer

Cytokine and Growth Factor Reviews

Volumn 23, Issue 3, 2012, Pages 127-138

  Li, Yi ^a,b   de Haar, Colin ^a   Peppelenbosch, Maikel P ^a   van der Woude, C Janneke ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

CRC; IBD; Immune regulation; SOCS3; STAT3

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 6; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; B LYMPHOCYTE ACTIVATION; BONE MARROW CELL; CANCER CELL CULTURE; COLORECTAL CANCER; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE ASSOCIATION; ENTERITIS; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; IMMUNOREGULATION; INNATE IMMUNITY; INTESTINE EPITHELIUM CELL; MACROPHAGE ACTIVATION; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE;

ADAPTIVE IMMUNITY; B-LYMPHOCYTES; COLORECTAL NEOPLASMS; DENDRITIC CELLS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; MACROPHAGES; NEUTROPHILS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; T-LYMPHOCYTES;

EID: 84861660536     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2012.04.005     Document Type: Review

References (140)

1. Loftus E.V. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004, 126:1504-1517.
2. Lakatos P.L. Recent trends in the epidemiology of inflammatory bowel diseases: up or down?. World Journal of Gastroenterology 2006, 12:6102-6108.
3. Duchmann R., Kaiser I., Hermann E., Mayet W., Ewe K., Meyer zum Buschenfelde K.H. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clinical and Experimental Immunology 1995, 102:448-455.
4. Garrett W.S., Gordon J.I., Glimcher L.H. Homeostasis and inflammation in the intestine. Cell 2010, 140:859-870.
5. Latiano A., Palmieri O., Latiano T., Corritore G., Bossa F., Martino G., et al. Investigation of multiple susceptibility loci for inflammatory bowel disease in an Italian cohort of patients. PLoS One 2011, 6:e22688.
6. Newman B., Siminovitch K.A. Recent advances in the genetics of inflammatory bowel disease. Current Opinion in Gastroenterology 2005, 21:401-407.
7. Schreiber S., Rosenstiel P., Albrecht M., Hampe J., Krawczak M. Genetics of Crohn disease, an archetypal inflammatory barrier disease. Nature Reviews Genetics 2005, 6:376-388.
8. Gordon J.N., Di Sabatino A., Macdonald T.T. The pathophysiologic rationale for biological therapies in inflammatory bowel disease. Current Opinion in Gastroenterology 2005, 21:431-437.
9. Shi J. Defensins and Paneth cells in inflammatory bowel disease. Inflammatory Bowel Diseases 2007, 13:1284-1292.
10. Crump B.C., Hopkinson C.S., Sogin M.L., Hobbie J.E. Microbial biogeography along an estuarine salinity gradient: combined influences of bacterial growth and residence time. Applied and Environment Microbiology 2004, 70:1494-1505.
11. Henderson P., van Limbergen J.E., Wilson D.C., Satsangi J., Russell R.K. Genetics of childhood-onset inflammatory bowel disease. Inflammatory Bowel Diseases 2011, 17:346-361.
12. Momozawa Y., Mni M., Nakamura K., Coppieters W., Almer S., Amininejad L., et al. Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. Nature Genetics 2011, 43:43-47.
13. Eaden J.A., Abrams K.R., Mayberry J.F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001, 48:526-535.
14. Eaden J. Review article: colorectal carcinoma and inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 2004, 20(Suppl. 4):24-30.
15. Saleh M., Trinchieri G. Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nature Reviews Immunology 2011, 11:9-20.
16. Bamias G., Nyce M.R., De La Rue S.A., Cominelli F. New concepts in the pathophysiology of inflammatory bowel disease. Annals of Internal Medicine 2005, 143:895-904.
17. Sartor R.B. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nature Clinical Practice Gastroenterology and Hepatology 2006, 3:390-407.
18. Rhodes J.M., Campbell B.J. Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends in Molecular Medicine 2002, 8:10-16.
19. Piessevaux J., Lavens D., Peelman F., Tavernier J. The many faces of the SOCS box. Cytokine and Growth Factor Reviews 2008, 19:371-381.
20. Babon J.J., McManus E.J., Yao S., DeSouza D.P., Mielke L.A., Sprigg N.S., et al. The structure of SOCS3 reveals the basis of the extended SH2 domain function and identifies an unstructured insertion that regulates stability. Molecular Cell 2006, 22:205-216.
21. Yoshimura A., Nishinakamura H., Matsumura Y., Hanada T. Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Research and Therapy 2005, 7:100-110.
22. Hebenstreit D., Horejs-Hoeck J., Duschl A. JAK/STAT-dependent gene regulation by cytokines. Drug News and Perspectives 2005, 18:243-249.
23. Li Y., de Haar C., Peppelenbosch M.P., van der Woude C.J. New insights into the role of STAT3 in IBD. Inflammatory Bowel Diseases 2011, [Epub ahead of print]. 10.1002/ibd.21884.
24. Endo T.A., Masuhara M., Yokouchi M., Suzuki R., Sakamoto H., Mitsui K., et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997, 387:921-924.
25. Naka T., Narazaki M., Hirata M., Matsumoto T., Minamoto S., Aono A., et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997, 387:924-929.
26. Aman M.J., Migone T.S., Sasaki A., Ascherman D.P., Zhu M., Soldaini E., et al. CIS associates with the interleukin-2 receptor beta chain and inhibits interleukin-2-dependent signaling. Journal of Biological Chemistry 1999, 274:30266-30272.
27. Ram P.A., Waxman D.J. SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. Journal of Biological Chemistry 1999, 274:35553-35561.
28. Kubo M., Hanada T., Yoshimura A. Suppressors of cytokine signaling and immunity. Nature Immunology 2003, 4:1169-1176.
29. Sasaki A., Yasukawa H., Shouda T., Kitamura T., Dikic I., Yoshimura A. CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. Journal of Biological Chemistry 2000, 275:29338-29347.
30. Schmitz J., Weissenbach M., Haan S., Heinrich P.C., Schaper F. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. Journal of Biological Chemistry 2000, 275:12848-12856.
31. Bjorbaek C., Buchholz R.M., Davis S.M., Bates S.H., Pierroz D.D., Gu H., et al. Divergent roles of SHP-2 in ERK activation by leptin receptors. Journal of Biological Chemistry 2001, 276:4747-4755.
32. De Sepulveda P., Okkenhaug K., Rose J.L., Hawley R.G., Dubreuil P., Rottapel R. Socs1 binds to multiple signalling proteins and suppresses steel factor-dependent proliferation. EMBO Journal 1999, 18:904-915.
33. Bayle J., Letard S., Frank R., Dubreuil P., De Sepulveda P. Suppressor of cytokine signaling 6 associates with KIT and regulates KIT receptor signaling. Journal of Biological Chemistry 2004, 279:12249-12259.
34. Greten F.R., Karin M. The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Letters 2004, 206:193-199.
35. Suzuki A., Hanada T., Mitsuyama K., Yoshida T., Kamizono S., Hoshino T., et al. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. Journal of Experimental Medicine 2001, 193:471-481.
36. Miyanaka Y., Ueno Y., Tanaka S., Yoshioka K., Hatakeyama T., Shimamoto M., et al. Clinical significance of mucosal suppressors of cytokine signaling 3 expression in ulcerative colitis. World Journal of Gastroenterology 2007, 13:2939-2944.
37. Sewell G.W., Marks D.J., Segal A.W. The immunopathogenesis of Crohn's disease: a three-stage model. Current Opinion in Immunology 2009, 21:506-513.
38. van Lierop P.P., Damen G.M., Escher J.C., Samsom J.N., Nieuwenhuis E.E. Defective acute inflammation in Crohn's disease. Lancet 2006, 368:578.
39. Brand S., Beigel F., Olszak T., Yoshioka K., Hatakeyama T., Shimamoto M., et al. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. American Journal of Physiology. Gastrointestinal and Liver Physiology 2006, 290:G827-G838.
40. Nagalakshmi M.L., Rascle A., Zurawski S., Menon S., de Waal Malefyt R. Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. International Immunopharmacology 2004, 4:679-691.
41. Ziesche E., Bachmann M., Kleinert H., Pfeilschifter J., Muhl H. The interleukin-22/STAT3 pathway potentiates expression of inducible nitric-oxide synthase in human colon carcinoma cells. Journal of Biological Chemistry 2007, 282:16006-16015.
42. Sugimoto K., Ogawa A., Mizoguchi E., Shimomura Y., Andoh A., Bhan A.K., et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. Journal of Clinical Investigation 2008, 118:534-544.
43. Ouyang W. Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease. Cytokine and Growth Factor Reviews 2010, 21:435-441.
44. Witte E., Witte K., Warszawska K., Sabat R., Wolk K. Interleukin-22: a cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection. Cytokine and Growth Factor Reviews 2010, 21:365-379.
45. Wolk K., Witte E., Wallace E., Docke W.D., Kunz S., Asadullah K., et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. European Journal of Immunology 2006, 36:1309-1323.
46. Bollrath J., Phesse T.J., von Burstin V.A., Putoczki T., Bennecke M., Bateman T., et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009, 15:91-102.
47. Ivory C.P., Wallace L.E., McCafferty D.M., Sigalet D.L. Interleukin-10-independent anti-inflammatory actions of glucagon-like peptide 2. American Journal of Physiology Gastrointestinal and Liver Physiology 2008, 295:G1202-G1210.
48. Linke A., Goren I., Bosl M.R., Pfeilschifter J., Frank S. The suppressor of cytokine signaling (SOCS)-3 determines keratinocyte proliferative and migratory potential during skin repair. Journal of Investigative Dermatology 2010, 130:876-885.
49. Linke A., Goren I., Bosl M.R., Pfeilschifter J., Frank S. Epithelial overexpression of SOCS-3 in transgenic mice exacerbates wound inflammation in the presence of elevated TGF-beta1. Journal of Investigative Dermatology 2010, 130:866-875.
50. Rigby R.J., Simmons J.G., Greenhalgh C.J., Alexander W.S., Lund P.K. Suppressor of cytokine signaling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon. Oncogene 2007, 26:4833-4841.
51. Smith M.F., Novotny J., Carl V.S., Comeau L.D. Helicobacter pylori and toll-like receptor agonists induce syndecan-4 expression in an NF-kappaB-dependent manner. Glycobiology 2006, 16:221-229.
52. White G.E., Cotterill A., Addley M.R., Soilleux E.J., Greaves D.R. Suppressor of cytokine signalling protein SOCS3 expression is increased at sites of acute and chronic inflammation. Journal of Molecular Histology 2010, 42:137-151.
53. Bode J.G., Nimmesgern A., Schmitz J., Schaper F., Schmitt M., Frisch W., et al. LPS and TNFalpha induce SOCS3 mRNA and inhibit IL-6-induced activation of STAT3 in macrophages. FEBS Letters 1999, 463:365-370.
54. Niemand C., Nimmesgern A., Haan S., Fischer P., Schaper F., Rossaint R., et al. Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. Journal of Immunology 2003, 170:3263-3272.
55. Uchiya K., Nikai T. Salmonella pathogenicity island 2-dependent expression of suppressor of cytokine signaling 3 in macrophages. Infection and Immunity 2005, 73:5587-5594.
56. Dalpke A.H., Opper S., Zimmermann S., Heeg K. Suppressors of cytokine signaling (SOCS)-1 and SOCS-3 are induced by CpG-DNA and modulate cytokine responses in APCs. Journal of Immunology 2001, 166:7082-7089.
57. Dalpke A., Zimmermann S., Heeg K. CpG-oligonucleotides in vaccination: signaling and mechanisms of action. Immunobiology 2001, 204:667-676.
58. Liu Y., Stewart K.N., Bishop E., Marek C.J., Kluth D.C., Rees A.J., et al. Unique expression of suppressor of cytokine signaling 3 is essential for classical macrophage activation in rodents in vitro and in vivo. Journal of Immunology 2008, 180:6270-6278.
59. Neurath M.F., Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine and Growth Factor Reviews 2011, 22:83-89.
60. Berlato C., Cassatella M.A., Kinjyo I., Gatto L., Yoshimura A., Bazzoni F. Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharide-induced macrophage activation. Journal of Immunology 2002, 168:6404-6411.
61. Mitsuyama K., Sata M., Rose-John S. Interleukin-6 trans-signaling in inflammatory bowel disease. Cytokine and Growth Factor Reviews 2006, 17:451-461.
62. Ishihara K., Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine and Growth Factor Reviews 2002, 13:357-368.
63. Yasukawa H., Ohishi M., Mori H., Murakami M., Chinen T., Aki D., et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nature Immunology 2003, 4:551-556.
64. Fang M., Dai H., Yu G., Gong F. Gene delivery of SOCS3 protects mice from lethal endotoxic shock. Cellular and Molecular Immunology 2005, 2:373-377.
65. Soehnlein O., Lindbom L. Phagocyte partnership during the onset and resolution of inflammation. Nature Reviews Immunology 2010, 10:427-439.
66. Ehlting C., Lai W.S., Schaper F., Brenndorfer E.D., Matthes R.J., Heinrich P.C., et al. Regulation of suppressor of cytokine signaling 3 (SOCS3) mRNA stability by TNF-alpha involves activation of the MKK6/p38MAPK/MK2 cascade. Journal of Immunology 2007, 178:2813-2826.
67. Dagvadorj J., Naiki Y., Tumurkhuu G., Noman A.S., Iftakhar E., Khuda I., et al. Tumor necrosis factor-a augments lipopolysaccharide-induced suppressor of cytokine signalling 3 (SOCS-3) protein expression by preventing the degradation. Immunology 2010, 129:97-104.
68. Starr R., Willson T.A., Viney E.M., Murray L.J., Rayner J.R., Jenkins B.J., et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997, 387:917-921.
69. Hortner M., Nielsch U., Mayr L.M., Johnston J.A., Heinrich P.C., Haan S. Suppressor of cytokine signaling-3 is recruited to the activated granulocyte-colony stimulating factor receptor and modulates its signal transduction. Journal of Immunology 2002, 169:1219-1227.
70. Kimura A., Kinjyo I., Matsumura Y., Mori H., Mashima R., Harada M., et al. SOCS3 is a physiological negative regulator for granulopoiesis and granulocyte colony-stimulating factor receptor signaling. Journal of Biological Chemistry 2004, 279:6905-6910.
71. Cassatella M.A., Tamassia N., Crepaldi L., McDonald P.P., Ear T., Calzetti F., et al. Lipopolysaccharide primes neutrophils for a rapid response to IL-10. European Journal of Immunology 2005, 35:1877-1885.
72. Iking-Konert C., Ostendorf B., Sander O., Jost M., Wagner C., Joosten L., et al. Transdifferentiation of polymorphonuclear neutrophils to dendritic-like cells at the site of inflammation in rheumatoid arthritis: evidence for activation by T cells. Annals of the Rheumatic Diseases 2005, 64:1436-1442.
73. Matsumura Y., Kobayashi T., Ichiyama K., Yoshida R., Hashimoto M., Takimoto T., et al. Selective expansion of foxp3-positive regulatory T cells and immunosuppression by suppressors of cytokine signaling 3-deficient dendritic cells. Journal of Immunology 2007, 179:2170-2179.
74. Croker B.A., Metcalf D., Robb L., Wei W., Mifsud S., DiRago L., et al. SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. Immunity 2004, 20:153-165.
75. Hwu P., Du M.X., Lapointe R., Do M., Taylor M.W., Young H.A. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. Journal of Immunology 2000, 164:3596-3599.
76. Orabona C., Belladonna M.L., Vacca C., Bianchi R., Fallarino F., Volpi C., et al. Cutting edge: silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant. Journal of Immunology 2005, 174:6582-6586.
77. Orabona C., Pallotta M.T., Volpi C., Fallarino F., Vacca C., Bianchi R., et al. SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:20828-20833.
78. Strengell M., Lehtonen A., Matikainen S., Julkunen I. IL-21 enhances SOCS gene expression and inhibits LPS-induced cytokine production in human monocyte-derived dendritic cells. Journal of Leukocyte Biology 2006, 79:1279-1285.
79. Li Y., Chu N., Rostami A., Zhang G.X. Dendritic cells transduced with SOCS-3 exhibit a tolerogenic/DC2 phenotype that directs type 2 Th cell differentiation in vitro and in vivo. Journal of Immunology 2006, 177:1679-1688.
80. Tuana G., Volpato V., Ricciardi-Castagnoli P., Zolezzi F., Stella F., Foti M. Classification of dendritic cell phenotypes from gene expression data. BMC Immunology 2011, 12:50.
81. Dimitriou I.D., Clemenza L., Scotter A.J., Chen G., Guerra F.M., Rottapel R. Putting out the fire: coordinated suppression of the innate and adaptive immune systems by SOCS1 and SOCS3 proteins. Immunological Reviews 2008, 224:265-283.
82. Ramgolam V.S., Sha Y., Jin J., Zhang X., Markovic-Plese S. IFN-beta inhibits human Th17 cell differentiation. Journal of Immunology 2009, 183:5418-5427.
83. Zhang X., Jin J., Peng X., Ramgolam V.S., Markovic-Plese S. Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. Journal of Immunology 2008, 180:6988-6996.
84. Hausding M., Tepe M., Ubel C., Lehr H.A., Rohrig B., Hohn Y., et al. Induction of tolerogenic lung CD4+ T cells by local treatment with a pSTAT-3 and pSTAT-5 inhibitor ameliorated experimental allergic asthma. International Immunology 2011, 23:1-15.
85. Banerjee A., Banks A.S., Nawijn M.C., Chen X.P., Rothman P.B. Cutting edge: Suppressor of cytokine signaling 3 inhibits activation of NFATp. Journal of Immunology 2002, 168:4277-4281.
86. Matsumoto A., Seki Y., Watanabe R., Hayashi K., Johnston J.A., Harada Y., et al. A role of suppressor of cytokine signaling 3 (SOCS3/CIS3/SSI3) in CD28-mediated interleukin 2 production. Journal of Experimental Medicine 2003, 197:425-436.
87. Yu C.R., Mahdi R.M., Ebong S., Vistica B.P., Gery I., Egwuagu C.E. Suppressor of cytokine signaling 3 regulates proliferation and activation of T-helper cells. Journal of Biological Chemistry 2003, 278:29752-29759.
88. Owaki T., Asakawa M., Kamiya S., Takeda K., Fukai F., Mizuguchi J., et al. IL-27 suppresses CD28-mediated [correction of medicated] IL-2 production through suppressor of cytokine signaling 3. Journal of Immunology 2006, 176:2773-2780.
89. Owaki T., Asakawa M., Fukai F., Mizuguchi J., Yoshimoto T. IL-27 induces Th1 differentiation via p38 MAPK/T-bet- and intercellular adhesion molecule-1/LFA-1/ERK1/2-dependent pathways. Journal of Immunology 2006, 177:7579-7587.
90. Egwuagu C.E., Yu C.R., Zhang M., Mahdi R.M., Kim S.J., Gery I. Suppressors of cytokine signaling proteins are differentially expressed in Th1 and Th2 cells: implications for Th cell lineage commitment and maintenance. Journal of Immunology 2002, 168:3181-3187.
91. Yamamoto K., Yamaguchi M., Miyasaka N., Miura O. SOCS-3 inhibits IL-12-induced STAT4 activation by binding through its SH2 domain to the STAT4 docking site in the IL-12 receptor beta2 subunit. Biochemical and Biophysical Research Communications 2003, 310:1188-1193.
92. Takatori H., Nakajima H., Kagami S., Hirose K., Suto A., Suzuki K., et al. Stat5a inhibits IL-12-induced Th1 cell differentiation through the induction of suppressor of cytokine signaling 3 expression. Journal of Immunology 2005, 174:4105-4112.
93. Seki Y., Inoue H., Nagata N., Hayashi K., Fukuyama S., Matsumoto K., et al. SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses. Nature Medicine 2003, 9:1047-1054.
94. Kinjyo I., Inoue H., Hamano S., Fukuyama S., Yoshimura T., Koga K., et al. Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1. Journal of Experimental Medicine 2006, 203:1021-1031.
95. Chen Z., Laurence A., Kanno Y., Pacher-Zavisin M., Zhu B.M., Tato C., et al. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:8137-8142.
96. Durant L., Watford W.T., Ramos H.L., Laurence A., Vahedi G., Wei L., et al. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity 2010, 32:605-615.
97. Wong P.K., Egan P.J., Croker B.A., O'Donnell K., Sims N.A., Drake S., et al. SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. Journal of Clinical Investigation 2006, 116:1571-1581.
98. Weaver C.T., Harrington L.E., Mangan P.R., Gavrieli M., Murphy K.M. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006, 24:677-688.
99. Fina D., Sarra M., Fantini M.C., Rizzo A., Caruso R., Caprioli F., et al. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology 2008, 134:1038-1048.
100. Qin H., Wang L., Feng T., Elson C.O., Niyongere S.A., Lee S.J., et al. TGF-beta promotes Th17 cell development through inhibition of SOCS3. Journal of Immunology 2009, 183:97-105.
101. Stumhofer J.S., Silver J.S., Laurence A., Porrett P.M., Harris T.H., Turka L.A., et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nature Immunology 2007, 8:1363-1371.
102. Kanda N., Kamata M., Tada Y., Ishikawa T., Sato S., Watanabe S. Human beta-defensin-2 enhances IFN-gamma and IL-10 production and suppresses IL-17 production in T cells. Journal of Leukocyte Biology 2011, 89:935-944.
103. Wehkamp J., Stange E.F., Fellermann K. Defensin-immunology in inflammatory bowel disease. Gastroenterologie Clinique et Biologique 2009, 33(Suppl. 3):S137-S144.
104. Pillemer B.B., Xu H., Oriss T.B., Qi Z., Ray A. Deficient SOCS3 expression in CD4+ CD25+ FoxP3+ regulatory T cells and SOCS3-mediated suppression of Treg function. European Journal of Immunology 2007, 37:2082-2089.
105. Lovato P., Brender C., Agnholt J., Kelsen J., Kaltoft K., Svejgaard A., et al. Constitutive STAT3 activation in intestinal T cells from patients with Crohn's disease. Journal of Biological Chemistry 2003, 278:16777-16781.
106. Kagami S., Owada T., Kanari H., Saito Y., Suto A., Ikeda K., et al. Protein geranylgeranylation regulates the balance between Th17 cells and Foxp3+ regulatory T cells. International Immunology 2009, 21:679-689.
107. Lodes M.J., Cong Y., Elson C.O., Mohamath R., Landers C.J., Targan S.R., et al. Bacterial flagellin is a dominant antigen in Crohn disease. Journal of Clinical Investigation 2004, 113:1296-1306.
108. Targan S.R., Landers C.J., Yang H., Lodes M.J., Cong Y., Papadakis K.A., et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 2005, 128:2020-2028.
109. Kobayashi K., Qiao S.W., Yoshida M., Baker K., Lencer W.I., Blumberg R.S. An FcRn-dependent role for anti-flagellin immunoglobulin G in pathogenesis of colitis in mice. Gastroenterology 2009, 137:1746-1756. e1741.
110. Noronha A.M., Liang Y., Hetzel J.T., Hasturk H., Kantarci A., Stucchi A., et al. Hyperactivated B cells in human inflammatory bowel disease. Journal of Leukocyte Biology 2009, 86:1007-1016.
111. Nishiwaki T., Ina K., Goto H., Watanabe O., Tsuzuki T., Furuta R., et al. Possible involvement of the interleukin-15 and interleukin-15 receptor system in a heightened state of lamina propria B cell activation and differentiation in patients with inflammatory bowel disease. Journal of Gastroenterology 2005, 40:128-136.
112. Gordon J.N., Pickard K.M., Di Sabatino A., Prothero J.D., Pender S.L., Goggin P.M., et al. Matrix metalloproteinase-3 production by gut IgG plasma cells in chronic inflammatory bowel disease. Inflammatory Bowel Diseases 2008, 14:195-203.
113. Schmidt E.G., Larsen H.L., Kristensen N.N., Poulsen S.S., Claesson M.H., Pedersen A.E. B cells exposed to enterobacterial components suppress development of experimental colitis. Inflammatory Bowel Diseases 2011, 18:284-293.
114. Schmidt E.G., Kristensen N.N., Claesson M.H., Pedersen A.E., Enteroantigen-presenting B cells efficiently stimulate CD4(+) T cells in vitro. Inflammatory Bowel Diseases 2011, 17:308-318.
115. Le Y., Zhu B.M., Harley B., Park S.Y., Kobayashi T., Manis J.P., et al. SOCS3 protein developmentally regulates the chemokine receptor CXCR4-FAK signaling pathway during B lymphopoiesis. Immunity 2007, 27:811-823.
116. Jones S.A., White C.A., Robb L., Alexander W.S., Tarlinton D.M. SOCS3 deletion in B cells alters cytokine responses and germinal center output. Journal of Immunology 2011, 187:6318-6326.
117. Grivennikov S.I., Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine and Growth Factor Reviews 2010, 21:11-19.
118. Niwa Y., Kanda H., Shikauchi Y., Saiura A., Matsubara K., Kitagawa T., et al. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 2005, 24:6406-6417.
119. Tokita T., Maesawa C., Kimura T., Kotani K., Takahashi K., Akasaka T., et al. Methylation status of the SOCS3 gene in human malignant melanomas. International Journal of Oncology 2007, 30:689-694.
120. He B., You L., Uematsu K., Zang K., Xu Z., Lee A.Y., et al. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:14133-14138.
121. Isomoto H. Epigenetic alterations in cholangiocarcinoma-sustained IL-6/STAT3 signaling in cholangio-carcinoma due to SOCS3 epigenetic silencing. Digestion 2009, 79(Suppl. 1):2-8.
122. Ogata H., Chinen T., Yoshida T., Kinjyo I., Takaesu G., Shiraishi H., et al. Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-beta1 production. Oncogene 2006, 25:2520-2530.
123. Isomoto H., Mott J.L., Kobayashi S., Werneburg N.W., Bronk S.F., Haan S., et al. Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology 2007, 132:384-396.
124. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., et al. IL-6 and stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
125. Li Y., de Haar C., Chen M., Deuring J., Gerrits M.M., Smits R., et al. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut 2010, 59:227-235.
126. Erreni M., Mantovani A., Allavena P. Tumor-associated Macrophages (TAM) and inflammation in colorectal cancer. Cancer Microenvironment 2011, 4:141-154.
127. Duluc D., Delneste Y., Tan F., Moles M.P., Grimaud L., Lenoir J., et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 2007, 110:4319-4330.
128. Sun Z., Yao Z., Liu S., Tang H., Yan X. An oligonucleotide decoy for Stat3 activates the immune response of macrophages to breast cancer. Immunobiology 2006, 211:199-209.
129. Wang Y.C., He F., Feng F., Liu X.W., Dong G.Y., Qin H.Y., et al. Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Research 2010, 70:4840-4849.
130. Hiwatashi K., Tamiya T., Hasegawa E., Fukaya T., Hashimoto M., Kakoi K., et al. Suppression of SOCS3 in macrophages prevents cancer metastasis by modifying macrophage phase and MCP2/CCL8 induction. Cancer Letters 2011, 308:172-180.
131. Lechner M.G., Liebertz D.J., Epstein A.L. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. Journal of Immunology 2010, 185:2273-2284.
132. Lechner M.G., Megiel C., Russell S.M., Bingham B., Arger N., Woo T., et al. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. Journal of Translational Medicine 2011, 9:90.
133. Medina-Echeverz J., Fioravanti J., Zabala M., Ardaiz N., Prieto J., Berraondo P. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. Journal of Immunology 2011, 186:807-815.
134. Iwata-Kajihara T., Sumimoto H., Kawamura N., Ueda R., Takahashi T., Mizuguchi H., et al. Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors. Journal of Immunology 2011, 187:27-36.
135. Zeng X., Kinsella T.J. Mammalian target of rapamycin and S6 kinase 1 positively regulate 6-thioguanine-induced autophagy. Cancer Research 2008, 68:2384-2390.
136. Zang Z.J., Ong C.K., Cutcutache I., Yu W., Zhang S.L., Huang D., et al. Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing. Cancer Research 2010, 71:29-39.
137. Sinicrope F.A., Rego R.L., Ansell S.M., Knutson K.L., Foster N.R., Sargent D.J. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 2009, 137:1270-1279.
138. Suzuki H., Chikazawa N., Tasaka T., Wada J., Yamasaki A., Kitaura Y., et al. Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer. Cancer Immunology, Immunotherapy 2010, 59:653-661.
139. Betts G., Jones E., Junaid S., El-Shanawany T., Scurr M., Mizen P., et al. Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut 2011, [Epub ahead of print].
140. Ladoire S., Martin F., Ghiringhelli F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunology, Immunotherapy 2010, 60:909-918.